The link between caveolae, metabolic syndrome, and cataractogenesis: A mechanistic hypothesis

Cataract, the leading cause of blindness worldwide, results from progressive lens opacification driven by oxidative stress, protein aggregation, and metabolic dysregulation. Although aging remains the primary risk factor, growing evidence implicates systemic metabolic disorders, particularly metabolic syndrome (MetS), in accelerating cataractogenesis. MetS, characterized by central obesity, hypertension, hyperglycemia, and dyslipidemia, promotes chronic inflammation, oxidative stress, and metabolic imbalance. These systemic disturbances create a biology milieu that lowers the threshold for crystallin oxidation and aggregation, thereby hastening cataract onset and progression. This article proposes a caveolae-centered mechanistic hypothesis to explain MetS-associated cataractogenesis. Caveolae are cholesterol-rich plasma membrane microdomains scaffolded by caveolin proteins and are increasingly recognized as key regulators of nutrient transport, insulin signaling, lipid trafficking, and oxidative stress regulation. Caveolae are present in lens epithelial cells, where MetS-induced disruption of caveolae integrity impairs insulin receptor and PI3K/Akt signaling, reduces glucose uptake, and compromises lens cell survival. Concurrently, loss of caveolae function may weaken antioxidant defenses and disrupt lipid homeostasis, promoting lipid peroxidation, membrane instability, and crystallin aggregation. Collectively, these alterations create a pro-cataractogenic microenvironment, linking systemic metabolic dysfunction to lens pathology through a distinct membrane-based pathway. By integrating evidence from metabolic biology, membrane signaling, and lens physiology, this hypothesis provides a unifying framework linking systemic metabolic dysfunction to cataract formation. Recognition of caveolae dysfunction as a nodal event in MetS-associated cataractogenesis may open new avenues for integrated preventive and therapeutic strategies targeting both metabolic diseases and age-related visual impairment.